Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History VTGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics VTGN

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

VistaGen Therapeutics Inc

VTGN
Current price
2.55 USD +0.05 USD (+2.00%)
Last closed 2.47 USD
ISIN US92840H2022
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 72 019 520 USD
Yield for 12 month -30.33 %
1Y
3Y
5Y
10Y
15Y
VTGN
21.11.2021 - 28.11.2021

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline comprises of Fasedienol(PH94B), an investigational pherine nasal spray for the treatment of anxiety in adults with social anxiety disorder which is in Phase III clinical trial; and Itruvone(PH10), an odorless synthetic investigational neuroactive pherine nasal spray for the treatment of major depressive disorder which is in Phase II clinical trial. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray with a novel for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders that is in Phase II clinical trial; PH15, an investigational pherine nasal spray with a novel for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders that is in Phase II clinical trial; and PH284, an odorless and tasteless synthetic investigational pherine nasal spray with a novel for the treatments of the loss of appetite associated with chronic disorders, such as cancer, heart disease, as well as cachexia that is in Phase II clinical trial. In addition, the company is developing an oral candidate, AV-101, an Oral NMDR glycine site antagonist for the treatment of depression and neurological disorders that is in phase I clinical trial. Further, its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California. Address: 343 Allerton Avenue, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

13.00 USD

P/E Ratio

Dividend Yield

Financials VTGN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures VTGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+486 000 USD

Last Year

+1 064 000 USD

Current Quarter

-15 000 USD

Last Quarter

+234 000 USD

Current Year

+486 000 USD

Last Year

+1 064 000 USD

Current Quarter

-15 000 USD

Last Quarter

+73 000 USD
EBITDA -55 823 000 USD
Operating Margin TTM 96 633.34 %
Price to Earnings
Return On Assets TTM -33.64 %
PEG Ratio
Return On Equity TTM -55.69 %
Wall Street Target Price 13.00 USD
Revenue TTM 486 000 USD
Book Value 2.43 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -43.10 %
Dividend Yield
Gross Profit TTM 486 000 USD
Earnings per share -1.67 USD
Diluted Eps TTM -1.67 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation VTGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 8.05
Price Sales TTM 148.19
Enterprise Value EBITDA -0.19
Price Book MRQ 1.02

Technical Indicators VTGN

For 52 Weeks

1.90 USD 4.01 USD
50 Day MA 2.30 USD
Shares Short Prior Month 478 074
200 Day MA 2.63 USD
Short Ratio 2.92
Shares Short 461 849
Short Percent 2.41 %